How Does Gastric Emptying Work?

Gastric emptying is the regulated transfer of gastric contents (chyme) from the stomach into the duodenum. In the research literature it is quantified as a rate or as a half-time (T½), most often the time required for 50% of a labelled test meal to leave the stomach. It is not a single molecular target but a physiological endpoint, and it is measured rather than assayed: standardized scintigraphy of a solid meal is one accepted method, and within-participant change in solid-meal T½ has been used as a primary outcome in surgical transit studies [4]. Because the endpoint is a rate, the evidence base is split between animal models, in which motility and neural circuitry can be manipulated directly, and human protocols, in which emptying is observed as an outcome of an intervention.

The work described below centres on vagal neurocircuitry — specifically the dorsal motor nucleus of the vagus (DMV) and its GABAergic inputs — together with the hormonal control of emptying by amylin and by glucagon-like peptide-1 (GLP-1) acting at the GLP-1 receptor (GLP-1R) [1][3][5].

Research Studies

Oestrogen and stress-induced vagally-dependent gastric responses in female rats

Gastric emptying was measured in female Sprague-Dawley rats across differing ovarian hormone states. Emptying was slower when oestrogen levels were high, and stress produced no further slowing in that condition [1]. Whole-cell recordings in the same work showed that oxytocin suppressed GABAergic transmission to DMV neurons under non-stressed conditions regardless of oestrogen level — a result the authors contrast with previous reports in male rats [1]. This is animal-only evidence; the DMV recordings are an in vitro electrophysiological measure, not a human emptying rate.

Amylin and slowing of gastric emptying

Amylin is a pancreatic β-cell hormone co-secreted with insulin. Among its reported actions are postprandial glucose regulation, slowing of gastric emptying, suppression of glucagon secretion, and promotion of satiation via central nervous system actions [3]. Long-acting amylin-based agents developed through peptide engineering, lipidation and reversible albumin binding include cagrilintide, eloralintide, petrelintide and NN1213, which differ in their pharmacokinetic properties [3]. The mechanistic claim here is hormonal and pharmacological; the source does not report a human emptying half-time for these agents.

GLP-1 receptor agonists and delayed gastric emptying

GLP-1R agonists are described as mimicking the natural hormone GLP-1, triggering pancreatic insulin release and delaying gastric emptying [8]. Both short-acting (exenatide/exendin-4) and long-acting (liraglutide, dulaglutide, semaglutide) GLP-1R agonists have been approved for type 2 diabetes and/or obesity [5]. Delayed emptying is therefore treated in this literature as a class property of GLP-1R agonism rather than a compound-specific finding.

GLP-1 and alcohol-related behaviours in preclinical models

Preclinical work has examined GLP-1 and its receptor in the pathophysiology of alcohol use disorder. Systemic treatment with exendin-4 reduced alcohol intake, the motivation to consume alcohol, and relapse-like behaviour in male animals, and alcohol consummatory behaviours were reduced in male or female animals treated with long-acting agonists [5]. This is animal evidence and concerns consummatory behaviour, not gastric emptying; it is included because it maps the same receptor system onto a different measured endpoint.

Endoscopic fundal mucosal ablation and gastric volume

The gastric fundus regulates appetite through orexigenic ghrelin-mediated and anorexigenic visceroceptive pathways, and endoscopic gastric fundal mucosal ablation (GFMA) is proposed to act on both. Ablation is also expected to cause shrinking of the fundus and reduce gastric volume, by analogy with mucosal ablation performed for other indications such as endoscopic submucosal dissection for tumour removal [2]. Separately, the same source notes that gastric emptying is a critical step in digestion found to be more rapid after prolonged exposure to a high-fat diet in both animal and human studies [2].

Transit bipartition after sleeve gastrectomy and solid-meal T½

A prospective single-centre study is evaluating adults undergoing revisional conversion from sleeve gastrectomy to intestinal transit bipartition, with forty participants completing clinical, endoscopic, physiological, metabolic, hormonal, imaging and stool assessments before surgery and during follow-up. The primary outcome is the within-participant change in solid-meal gastric emptying half-time (T½) by standardized scintigraphy from baseline to 6 months. Secondary and exploratory outcomes include reflux symptoms, DeMeester score and acid exposure, route-specific gastric transit, GLP-1 and ghrelin responses, glucose metabolism, fecal elastase, gut microbiota and body-weight trajectory [4].

Mechanical ventilation-associated gastrointestinal dysfunction

In intensive care, more than 60% of mechanically ventilated patients experience gastrointestinal dysfunction. Proposed contributors include increased intra-abdominal pressure from positive-pressure ventilation inhibiting gastrointestinal motility, inflammatory responses, prolonged bed rest, electrolyte imbalances, and the use of sedatives, analgesics and muscle relaxants; gastroparesis and constipation are among the manifestations [6]. A registered study is examining neostigmine acupoint injection at Zusanli (ST36) in this population [6].

Simulated microgravity and functional dyspepsia in rats

Thirty male Wistar rats were randomly assigned to control, hindlimb-unloading (HU) and domperidone groups, with the HU model induced by 21-day tail suspension as a ground-based platform for simulating microgravity. Behavioural tests included sucrose preference and novelty-suppressed feeding, alongside gastrointestinal motility and brain-gut peptide measures [7]. This is an animal model of functional dyspepsia; the motility findings are not human emptying data.

Comparison of emptying-relevant interventions

If you are reading this for personal health reasons

The materials described here are supplied for laboratory research use only. We do not provide dosing information, medical guidance, or recommendations for personal use of any compound. Anyone considering a compound for themselves should speak to a licensed clinician.

Sources

• [1] Oestrogen modulates stress-induced vagally-dependent gastric responses to oxytocin — https://europepmc.org/article/PMC/PMC13577686
• [2] Bariatric Endoscopic Antral Myotomy Combined With Fundal Gastric Mucosal Ablation — https://clinicaltrials.gov/study/NCT07612527
• [3] Beyond GLP-1: Amylin-based pharmacotherapy and the search for better-tolerated weight-loss drugs — https://pubmed.ncbi.nlm.nih.gov/42586227/
• [4] Transit Bipartition After Sleeve Gastrectomy — https://clinicaltrials.gov/study/NCT07728682
• [5] GLP-1 and Alcohol-Related Behaviors: Insights From Preclinical Studies — https://pubmed.ncbi.nlm.nih.gov/42461204/
• [6] Study on Neostigmine Acupoint Injection at Zusanli(ST36) for Treating Mechanical Ventilation-Associated Gastrointestinal Dysfunction — https://clinicaltrials.gov/study/NCT07692282
• [7] Tail-Suspension Model of Simulated Microgravity-Induced Functional Dyspepsia in Rats — https://europepmc.org/article/PMC/PMC13256725
• [8] A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device in Obese Patients With Endometrioid Intraepithelial Neoplasia — https://clinicaltrials.gov/study/NCT07107334